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Despite much recent interest  and effort, the role played by major histocom- 
patibility  complex  products  in  the  regulation  of  T-cell  responses  remains 
perplexing.  In  1972  it  was  observed  that  mouse  T  and  B  cells  would  only 
cooperate  in  an  antibody  reponse  if they  shared  certain  regions  of H-2  (1). 
Subsequently, H-2 gene products were also found to be involved in cytotoxic T- 
cell  reactions,  and  it  was  postulated  that  the  killer  T  cell  must  bear  H-2 
molecules in common with those of its target in order to effect lysis (2-6). Later 
studies with radiation chimeras showed that this is not the case, but that the H- 
2 region must be shared between the cells used to stimulate the response and 
the targets; a killer T cell that was itself H-2 type A, after having grown up in 
an  (A  ×  B)F1  could  be  stimulated  to  lyse  H-2  type  B  virus-infected  or 
trinitrophenyl-modified targets (7-9). Such chimeras were also found to contain 
A type helper T cells which can cooperate with B type B cells (10).  It was then 
postulated that T-cell precursors "learn" to recognize the H-2 type of the host as 
self (11).  Recent  evidence  shows  that  the  host  H-2  type  of a  chimera  does 
distinctly influence the specificity of the responding T-cell population  (12,  13) 
and that  it is the H-2 type of the thymus that  is important  (13).  Most of this 
work has been done with semiallogeneic chimeras  (e.g., "A" bone marrow into 
an irradiated  [A  ×  B]F, or [A  ×  B]F1 bone marrow into an "A" or [A  ×  C]F1) 
where the responses were very strongly restricted by the H-2 type of the host. A 
small  number  of completely  allogeneic  chimeras  was  tested  (e.g.,  "A"  bone 
marrow  into  "B")  and  appeared  to  be  immunoincompetent.  The  virtually 
absolute restriction of the semiallogeneic chimeras as well as the immunoincom- 
petence of the fully allogeneic chimeras has led to much speculation  and has 
been  quoted  as  suggestive  evidence  for  the  dual  recognition  model  of T-cell 
receptors (13). 
We report here that in contrast to the results with virus-infected mice, fully 
allogeneic chimeras made by repopulating irradiated  BALB/c(H-2  d) mice with 
BALB.B(H-2  b) bone marrow are well able to respond to minor histocompatibility 
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(H)  2 antigens,  and that the killer T cells that are themselves H-2  b can recognize 
minor H  antigens on either H-2  b or H-2 d targets. 
Materials and Methods 
Mice.  C57BL/10Sn(H-2 b)  (B10),  B10.D2/nSn(H-2d),  B10.G(H-2q),  B10.BR/SgSn(H-2k),  and 
D1.C(H-2 d) mice were purchased from The Jackson Laboratory, Bar Harbor, Maine. The BALB/ 
cKe(H-2 d)  (C),  and BALB.B(H-2 b)  (C.B.)  mice used for making the chimeras were bred at the 
Salk Institute,  San Diego,  Calif.  The C,  C.B,  BALB.K(H-2 k)  (C.K),  and (BALB/c  x  BALB.B) 
(C x  C.B) used for target and stimulater cells were bred at the University of California San Diego, 
from breeding pairs generously given to us by Dr. Frank Lilly (Albert Einstein Medical College, 
N.Y.). 
Relationship of BlO Series, BALB Series, and DBA/1  Series Mice.  B10, B10.D2, B10.BR, and 
B10.G differ genetically by a small segment of chromosome 17 which carries the H-2 gene complex 
and Tla, and are otherwise probably identical (14,  15).  D1.C is a  congenic line made by putting 
the H-2  d of BALB/c on the DBA/1 background. D1.C has some minor H antigens in common with 
the B10 series mice that are not expressed by BALB/c, and was sometimes used as a  substitute 
for B10.D2 which were in short supply. 
C, C.B, and C.K also differ only at the H-2 gene complex. The C mice from Salk Institute differ 
from those of Lilly in that they possess some minor H  antigen differences which were discovered 
when some Salk C  mice immunized with B10.D2 showed slight activity on C  mice from Lilly. 
In general, such differences were not a problem although every so often we came across a chimera 
which had slight cytotoxic activity on Lilly C, C.B, or (C  x  C.B)FI targets. 
Chimeras.  20 C  c~ mice were given 900 rads from a  Cobalt 60 source and immediately given 
an i.v. injection of 107 C.B pooled 9  +  c~ viable bone marrow cells. T cells were removed from the 
marrow by treatment with AKR anti-C3H (anti-Thy 1.2) serum (15 min, 4°C) followed by agarose- 
absorbed guinea pig complement (45 min, 37°C).  11 of these chimeras were used between 5 wk and 
13 mo after reconstitution. A total of 17 chimeras survived for more than 4 mo. 
Testing Chimerism.  The presence of host cells in chimeric spleen cell suspensions was assayed 
before in vitro culture with a cytotoxic antiserum (C57BL/6 anti-P815 (H-2 d) (kindly given us by 
Joseph Coha,  University of California San Diego).  Spleen cells were incubated with antiserum 
and selected nontoxic rabbit complement for 45 min at 37°C.  The ratio of viable to dead cells was 
determined using trypan blue. On each test, positive and negative control cells were included to 
ensure the specificity and activity of the antiserum. 
The H-2 type of the cytotoxic effeetor cells generated in vitro was tested just before the s~Cr 
release assay, using antisera produced,  absorbed, and extensively tested in functional assays by 
Dr.  Michael Bevan,  Center for Cancer Research,  Massachusetts Institute of Technology,  Cam- 
bridge, Mass. We used his C.B anti-B10.D2(aH-2  d) and C3H  x  DBA/2 anti-C.B(aH-2b). The test 
cells were washed, resuspended to 12  x  106 viable cells/ml, incubated with antiserum at 4°C for 
30 min, centrifuged, and resuspended in guinea pig C for 45 min at 37°C.  They were then washed 
twice, resuspended in equal volumes, and titrated against :'~Cr-labeled targets. 
Immunizations.  Chimeras were primed by injection of 107 viable spleen cells i.p.  in Hanks' 
balanced salt solution and tested in culture from 3 wk to 12 mo later without apparent differences 
in response. 
Cytotoxic Assay.  Spleen cells from primed chimeras were cultured for 5 days at a  ratio of 4:1 
with mitomycin C-treated stimulator spleen cells as described  (4),  and were then washed once 
before use in the 51Cr release assay. 
Serial dilutions of such in vitro-boosted cells were then titrated against 4  x  104 s~Cr-labeled 
concanavalin A (Con A) blasts (4, 16). The percentage of specific release after 3 to 5 h of incubation 
was calculated as: 
% specific release =  experimental release (cpm)  -  spontaneous release (cpm)  x  100. 
total incorporated (cpm) -  spontaneous release (cpm) 
Spontaneous  release  varied  from  9.6  to  35.6%  of total  in  different experiments.  The  greatest 
differences we saw in spontaneous release for different targets within a  single experiment was 
8%.  When effector:target ratio is given, the effector number is based on the number of primed 86  CHIMERA  RESPONSE  TO  MINOR  HISTOCOMPATIBILITY  ANTIGENS 
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FIG.  1.  Cytotoxic  activity of C.B --~ C  chimeric spleen cells primed in vivo with D1.C, 
cultured against (B10 ×  B10.D2)F~  or BALB.K (C.K) stimulator spleen cells, and tested on 
51Cr-labeled B10.D2 (O), B10 (@), B10.BR (A), or (C x  C.B)F1 (A) Con A blasts. 
cells originally put into the boosting culture, not viable cells recovered. Recovery varied from 20 
to 60% in different experiments. 
Results 
Can Fully Allogeneic Chimeras Respond to Minor H Antigens?  Spleen cells 
from a  C.B --+ C chimera, primed with 15  x  10  s D1.C spleen cells 5 wk after 
reconstitution, were checked for the presence of residual host H-2 d cells and 
were found to contain <1%. The cells were then cultured with (B10 x  B10.D2)F] 
or C.K stimulatory cells for 5 days before testing on B10, B10.D2,  B10.BR, or (C 
x  C.B)F1 targets. As illustrated in Fig.  1, the cytotoxic T lymphocytes (CTL) 
cultured with (B10 x  B10.D2)F1 stimulators lysed B10.D2 targets very well and 
had no activity on (C  x  C.B)F1,  B10,  or B10.BR targets. Thus these CTL are 
specific for the combination of minor H  +  H-2 d.  The CTL cultured with C.K 
lysed B10.BR specifically, showed a slight cross reaction on B10.D2,  and had no 
activity on B10 or (C x  C.B)F1.  A similar cross reaction has been noticed before 
in normal C mice primed against B10.D2  and tested on B10.BR or C.K targets 
(16),  and has been extensively studied elsewhere (17). It appears then that a 
fully allogeneic chimera can respond to minor H  antigens and is tolerant to 
both marrow donor and host type cells. 
Can  These  Chimeras  Respond  to  Minor H  Antigens  in  Combination  with 
Either H-2 b or H-2 d?  In the previous experiment, cross priming should have 
led to priming of anti-B10 CTL, which should then have been boosted in the 
culture with (B10  x  B10.D2)F~  stimulators (16); however, no killing was seen 
on B10 targets. This could have been explained in three ways. Either (a) there 
really were no CTL precursors capable of responding to B10,  (b) anti-B10 CTL P.  MATZINGER  AND  G.  MIRKWOOD  87 
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FIG.  2.  Cytotoxic activity of C.B --* C  chimeric spleen cells primed in vivo with D1.C, 
cultured with B10, B10.D2,  or B10.G spleen cell stimulators, and tested on 51Cr-labeled B10 
(©), B10.D2  (e), or B10.G (A) Con A blasts. 
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precursors did exist but cross priming had not occurred, or (c)  such CTL did 
exist and were primed but were such a minority population that they were not 
boosted well by the (B10 × B10.D2)F1 stimulators. We therefore decided to boost 
with B10 and B10.D2  separately to see whether we could raise a  population of 
effector cells against B10. 
Spleen cells from a chimera primed with D1.C were checked for the presence 
of H-2 d positive cells, found to be  <1% positive, and then cultured with B10, 
B10.D2,  or B10.G stimulators for 5 days before testing on B10,  B10.D2,  and 
B10.G targets. Fig. 2 shows that the CTL cultured with B10 stimulators lysed 
B10 cells, CTL cultured with B10.D2 lysed B10.D2 cells, and those cultured with 
B10.G lysed B10.G. The activity seen on B10, although sixfold lower than that 
on  B10.D2  targets,  is  quite  good.  It  seemed  that  we  had  two  responding 
populations in the chimeras primed with D1.C,  a  large (or very active) set of 
CTL precursors against B10.D2  and a  smaller (or less active) set against B10. 
This  shows  that  C.B  -->  C  chimeric T  cells  that  have  grown  up  under  the 
influence of an H-2 d thymus can nevertheless react against minor H  antigens 
plus H-2 b. It also indicates that the type of  boost given may be important. When 
the population ofT cells one is looking for is likely to be small, it may be best to 
immunize in a  way that will expand that population preferentially over other 
possible responders. 
Table  I  is  a  summary of results from eight chimeras primed  against  B10 
minor H antigens and boosted in vitro with either (B10 x  B10.D2)F1 or B10 and 
B10.D2  separately.  In lines  1-4  there is virtually no activity on B10  targets 
whereas B10.D2 targets are lysed very well. From such data we could conclude 
that these chimeras are  only able to respond to minors presented with H-2 d 
(even though cross priming should have led to activity on B10). However, lines 88  CHIMERA  RESPONSE  TO  MINOR  HISTOCOMPATIBILITY  ANTIGENS 
TABLE  I 
The H-2 Type of CeUs Used to Prime and Boost Influences the Cytotoxic 
Responses Detected in H-2 Incompatible C.B ---* C Chimeras* 
Aggressor:  Specific  51Cr release 
Expori-  Primed with  Boosted  with  target ra- 
ment$  tio  B10  B10.D2 
75  B10.D2  (B10 x B10.D2)  8:1  0.6  63 
75a  B10.D2  "  6:1  3.3  60.4 
47  D1.C  "  142:1  -2.0  18.5 
67  D1.C  "  50:1  3.6  76.0 
B10  147:1  33.2  0.4  62  D1.C  B10.D2  147:1  -8.0  56.0 
B10  97:1  23.0  -2.4  59  D1.C  B10.D2  49:1  1.5  65.2 
67a  B10  (B10 x B10.D2)  50:1  31.6  12.8 
B10  147:1  15.0  -1.3  62a  B10  B10.D2  147:1  -4.6  7.9 
* Chimeras  were primed in vivo and boosted in vitro  (for 5 days) with  spleen cells and 
tested in a 4-h ~lCr release assay. Although each assay was done as a titration,  we report 
only one ratio here for convenience. No significant activity was seen on C, C.B, or (C x 
C.B)F1 targets. 
Each number represents  an individual mouse. 
5-11 negate such a  conclusion and show that the antigen used to prime or boost 
can  definitely  influence  the  response.  Mice  primed  with  minor  +  H-2 d and 
boosted with  B10 definitely respond to  B10,  as  do mice primed  with  B10  and 
boosted with the FI(B10  x  B10.D2).  It appears that CTL precursors reactive to 
B10 do exist and can be seen if their numbers are expanded preferentially either 
in the priming or boosting immunizations. 
Are the Effector Cells Entirely of Donor Origin?  Even though we could not 
detect any residual host cells in the chimeric spleens, the possibility remained 
that they did exist in small numbers, were expanded during culture,  and were 
responsible for at least some of the activity we saw after 5 days. We therefore 
killed the effector cells just before the 51Cr release assay with antiserum against 
H-2 b or H-2 d +  C to see whether any activity was due to H-2 ~ positive cells. 
The antisera were previously tested on C anti-C.B and C.B anti-C CTL using 
exactly the same protocol and reagents used here and were found to eliminate 
the  activity of the  appropriate  effector cells  completely  (M.  Bevan,  personal 
communication). 
Spleen cells from two chimeras that had been primed with B10.D2 7 mo after 
reconstitution  (ample time for the host to regenerate if it were going to) were 
cultured 6 mo later with (B10  x  B10.D2)F~ or B10.G stimulators.  After 5 days, 
a sample of each culture was assayed on B10, B10.D2, B10.G, C, and C.B targets 
and both chimeras were found to have some activity specific for B10, excellent 
activity on B10.D2  and  B10.G targets,  and none on C  or C.B.  The remaining 
B10.D2-boosted CTL were then treated with anti-H-2 b or anti-H-2 d plus C  and 
titrated on B10.D2 targets. 
Fig.  3  shows that  CTL treated  with  anti-H-2 d +  C  were  completely active P.  MATZINGER  AND  G.  MIRKWOOD  89 
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FIG.  3.  Effect of treatment with anti-H-2  b or anti-H-2  d serum + C on the ability of C.B --* 
C" chimeric CTL to mediate lysis. These CTL were primed in vivo with B10.D2,  cultured 
with B10.D2  stimulators for 5 days, treated with antiserum +  C, C alone, or left untreated 
and then tested for their ability to lyse 5~Cr-labeled B10.D2  targets. 
whereas those treated with anti-H-2  b +  C were no longer able to function. Thus 
there is no detectable contribution by the irradiated host to the CTL activity we 
see. All the activity against B10.D2 must be due to H-2 b T cells. 
Discussion 
We began our experiments to ask whether H-2 b T cells could respond to minor 
histocompatibility antigens associated with H-2 d in a fully allogeneic chimera, 
and also to ask whether cross priming occurred in these animals. We found that 
these chimeras do respond to minor H  antigens on beth H-2 types, they give 
allogeneic reactions, they exhibit a  type of cross-reactivity seen in normal C 
and (C  × C.B) mice, and they can be cross primed. In every aspect but one they 
have the  same  CTL responses  as  a  perfectly normal  (C  x  C.B)F1.  The one 
difference is that, although they have a population of CTL precursors which can 
be activated against minor H  +  H-2 b (B10), they do show some preference for 
minor +  H-2 d (B10. D2). This, from the results of Bevan (12) and Zinkernagel et 90  CHIMERA  RESPONSE  TO  MINOR  HISTOCOMPATIBILITY  ANTIGENS 
al.  (13) would be expected ofT cells that have grown up in an H-2 d thymus. 
The present results  differ from those reported by Zinkernagel  et al.  in two 
important  and  related  respects.  Firstly,  like  Bevan,  we find  a  preference  in 
CTL  activity  toward  antigen  in  association  with  host  H-2  rather  than  the 
virtually absolute restriction reported by Zinkernagel et al.  Secondly, whereas 
fully allogeneic chimeras were reported to be immunoincompetent  (13), we find 
that  they  are  completely capable  of responding  to  minor  H  antigens  and  to 
foreign H°2. There are technical differences between our systems that could lead 
to these disparities. 
(a)  Zinkernagel  et  al.  looked  at  an  in  vivo primary  response  whereas  we 
assay a secondary response in vitro. Perhaps a boost is required to raise effector 
cell  levels  to  those  that  can  be  detected  in  a  ~lCr  release  assay.  Thus  the 
population  capable  of responding  to  B10  in  C.B  ~  C  chimeras  would  be 
undetectable without specific priming or boosting (Table I, Fig. 2). 
(b)  After inoculation with live virus, host cells must present viral antigen to 
CTL precursors.  A  host antigen-presenting  system may not be necessary for 
direct priming against minor H  antigens on spleen cells and the priming may 
be more efficient as a consequence. Thus, a chimera may respond detectably to 
minor H antigens while it remains unresponsive to viral antigens. 
(c)  The apparent  immunoincompetence of fully allogeneic chimeras in viral 
systems was explained by postulating that  CTL precursors require a  helper T 
cell to be activated (13).  In our case, therefore,  T helpers,  having grown up in 
an  H-2 d thymus,  should be restricted to seeing antigen  in the context of H-2 d 
and  should  not  be  able  to  give  assistance  to  the  H-2 b repopulating  CTL 
precursors.  It  is  possible that  an  injection  of B10.D2  spleen  cells  leads  to  a 
positive  allogeneic  effect  against  the  H-2 b CTL,  thereby  sidestepping  any 
requirement  for T  helpers.  We feel this  is unlikely because it was previously 
shown  (16)  that  an  allogeneic  effect  is  neither  necessary  nor  sufficient  for 
priming against minor H  antigens.  In any case, B10 spleen cells should not be 
able to give a positive allogeneic effect against the C.B. CTL, and yet they are 
perfectly able to prime these chimeras. 
It is impossible to exclude altogether a role for mature T cells contaminating 
the marrow inoculum,  despite the treatment  with anti-Thy-1  +  C.  In theory, 
such mature helper T cells, having grown up in an H-2 b thymus, could retain 
complete restriction to H-2 b and thus provide help for contaminating mature H- 
2 b CTL precursors which were themselves H-2 b restricted, or for CTL precursors 
grown up in the host thymus, completely restricted to H-2 d. This interpretation 
seems  unlikely  on  quantitative  grounds,  but  must  be  berne  in  mind  when 
absolute restrictions are not seen. 
We feel rather that the restriction imposed by the thymus is profound but not 
absolute,  so that  an  H-2 d mouse does have  some T-cell  precursors  capable of 
reacting to antigen  +  H-2 b (or H-2 q or H-2 s etc.) and that these precursors will 
be found in all classes of T cells. Therefore, if T helpers are necessary for CTL 
function, our fully allogeneic chimeras must have an adequate supply of such T 
helpers. 
In summary we have found that congenic,  fully H-2 incompatible radiation 
chimeras,  primed  in  vivo  and  boosted  in  vitro  with  cells  bearing  minor  H P.  MATZINGER  AND  G.  MIRKWOOD  91 
differences,  produce  H-2-restricted  cytotoxic  cells  specific  for  the  minor  H 
antigens. The specificity of  restriction can be either to donor or host H-2 and the 
activity observed depends on the H-2 type of the cells used to prime or boost. 
Summary 
Fully  H-2  incompatible  radiation  chimeras  were  prepared  using  BALB 
congenic mice. Such chimeric mice were immunized in vivo against histocom- 
patibility antigens of the  C57BL/10Sn  (B10) background in  association with 
either  of the  parental  H-2  haplotypes,  and  their  spleen  cells  subsequently 
boosted in vitro with the same minor antigens. Strong H-2-restricted cytotoxic 
activity against minor antigens was detected, and the specificity of the restric- 
tion could be to the H-2 haplotype of  the donor or the host depending on the cells 
used for priming or boosting. Cross priming could also be demonstrated in these 
mice. The results show that fully allogenic radiation chimeras can produce H-2- 
restricted T-cell responses to minor histocompatibility (H)  antigens, and are 
discussed  in  relation  to  contrasting results  recently obtained  against  viral 
antigens. 
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